For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions (NCT07275814) | Shanghai Shengdi Pharmaceutical Co., Ltd | 2025-11-17 |
| A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions (NCT06731829) | Jiangsu HengRui Medicine Co., Ltd. | 2024-12-01 |
Track For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions automatically
Every clearance here is in the API, with alerts when new ones post.